Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Annovis Bio, Inc. ANVS
$14.19
-$0.62 (-4.38%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
134176437.00000000
-
week52high
23.91
-
week52low
8.39
-
Revenue
0
-
P/E TTM
-14
-
Beta
1.20770000
-
EPS
-3.16000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 12:30
Описание компании
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Ladenburg Thalmann | Buy | 02 мая 2022 г. | |
| HC Wainwright & Co. | Buy | 08 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Hagopian Henry III | A | 7672 | 7672 | 18 янв 2023 г. |
| Maccecchini Maria-Luisa | A | 21312 | 21312 | 18 янв 2023 г. |
| Bruck Claudine | A | 5967 | 5967 | 18 янв 2023 г. |
| Hoffman Michael B | A | 6820 | 6820 | 18 янв 2023 г. |
| McCarthy Reid | A | 5967 | 5967 | 18 янв 2023 г. |
| White Mark K. | A | 5967 | 5967 | 18 янв 2023 г. |
| Hagopian Henry III | A | 120000 | 120000 | 29 авг 2022 г. |
| Maccecchini Maria-Luisa | D | 52755 | 32959 | 14 янв 2022 г. |
| Maccecchini Maria-Luisa | A | 987734 | 32959 | 14 янв 2022 г. |
| Hoffman Michael B | D | 0 | 7142 | 04 янв 2022 г. |
Новостная лента
Annovis Bio to Present at the 2022 ThinkEquity Investor Conference
PRNewsWire
20 окт 2022 г. в 07:30
BERWYN, Pa. , Oct. 20, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the ThinkEquity 2022 Investor Conference on Wednesday, October 26, 2022, in New York City.
Annovis (ANVS) Gains on FDA Authorization for AD Study
Zacks Investment Research
07 окт 2022 г. в 14:18
Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).
Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look
Seeking Alpha
06 окт 2022 г. в 00:31
Green light received from the FDA to initiate a phase 3 study using buntanetap for the treatment of early-stage Parkinson's Disease patients. The global Parkinson's Disease market is expected to reach $8.38 billion by end of 2026.
Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study
Zacks Investment Research
25 авг 2022 г. в 14:18
Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.
Annovis Bio to Present at the Alzheimer's Association International Conference
PRNewsWire
14 июл 2022 г. в 07:30
Maria Maccecchini, Ph.D., Founder, President, and CEO, will be participating on a panel discussing the Systems Biology of Alzheimer's Disease moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, Ph.D.